

Randy D Gascoyne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3645709/publications.pdf>

Version: 2024-02-01

711
papers

92,576
citations

315

138
h-index

326

287
g-index

741
all docs

741
docs citations

741
times ranked

60808
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
2	Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. <i>Blood</i> , 2021, 137, 2196-2208.	0.6	18
3	Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma. <i>Blood</i> , 2021, 137, 1256-1259.	0.6	13
4	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 267-278.e10.	0.2	8
5	Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 1466-1471.	1.7	9
6	Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines. <i>Blood Advances</i> , 2021, 5, 1483-1489.	2.5	17
7	Characterization of DLBCL with a PMBL gene expression signature. <i>Blood</i> , 2021, 138, 136-148.	0.6	19
8	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	0.8	132
9	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. <i>Haematologica</i> , 2021, 106, 2682-2693.	1.7	44
10	Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach. <i>Blood Advances</i> , 2021, 5, 3647-3655.	2.5	4
11	Gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma. <i>Blood</i> , 2021, , .	0.6	9
12	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, e72-e75.	1.7	11
13	Single Cell Phenotypic Profiling of 27 DLBCL Cases Reveals Marked Intertumoral and Intratumoral Heterogeneity. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 620-629.	1.1	12
14	Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 657-664.	2.1	21
15	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. <i>Clinical Cancer Research</i> , 2020, 26, 4468-4477.	3.2	16
16	TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. <i>Nature Medicine</i> , 2020, 26, 577-588.	15.2	46
17	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. <i>Blood</i> , 2020, 136, 572-584.	0.6	44
18	The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 34-34.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2019, 134, 802-813.	0.6	96
20	Targetable genetic alterations of <i>TCF4</i> (<i>E2-2</i>) drive immunoglobulin expression in diffuse large B cell lymphoma. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	51
21	Prognostic Significance of <i>MYC</i> Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2019, 37, 3359-3368.	0.8	161
22	The whole-genome landscape of Burkitt lymphoma subtypes. <i>Blood</i> , 2019, 134, 1598-1607.	0.6	113
23	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. <i>Cancer Discovery</i> , 2019, 9, 546-563.	7.7	213
24	Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival. <i>Lupus Science and Medicine</i> , 2019, 6, e000324.	1.1	16
25	Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. <i>Haematologica</i> , 2019, 104, e558-e561.	1.7	55
26	Identification of high-risk <i>DUSP22</i> rearranged <i>ALK</i> -negative anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e28-e31.	1.2	56
27	Follicular lymphoma patients with <i>KIR2DL2</i> and <i>KIR3DL1</i> and their ligands (<i>HLA-C1</i> and <i>HLA-Bw4</i>) show improved outcome when receiving rituximab. , 2019, 7, 70.		19
28	Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 190-201.	0.8	257
29	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. <i>Blood</i> , 2019, 133, 1664-1676.	0.6	184
30	Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray. <i>Blood Advances</i> , 2019, 3, 3953-3961.	2.5	22
31	<i>JUNB</i> , <i>DUSP2</i> , <i>SGK1</i> , <i>SOCS1</i> and <i>CREBBP</i> are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma. <i>Haematologica</i> , 2019, 104, 330-337.	1.7	45
32	Convergence of risk prediction models in follicular lymphoma. <i>Haematologica</i> , 2019, 104, e252-e255.	1.7	9
33	TP53 Expression Correlates with TP53 Mutations and Is an Independent Predictor of Clinical Outcome in Patients with DLBCL Treated with R-CHOP. <i>Blood</i> , 2019, 134, 3964-3964.	0.6	2
34	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	0.6	4
35	Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6511-6511.	0.8	0
36	Abstract 3765: Somatic JAK-STAT mutations in subtypes of aggressive B-cell lymphomas with DLBCL morphology. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome. <i>Blood</i> , 2019, 134, 922-922.	0.6	1
38	Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study. <i>Blood</i> , 2019, 134, 3475-3475.	0.6	0
39	Molecular Correlates of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2763-2763.	0.6	0
40	Mutations Affecting RNA Binding Proteins Are a Novel Feature of Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 1478-1478.	0.6	0
41	Abstract 3480: <i>TMEM30A</i> loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. , 2019, , .		0
42	Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. <i>Blood</i> , 2018, 131, 2036-2046.	0.6	39
43	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> , 2018, 131, 2060-2064.	0.6	167
44	Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 203-214.	1.2	58
45	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1396-1407.	13.9	1,443
46	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. <i>Nature Communications</i> , 2018, 9, 222.	5.8	51
47	Impact of age on genetics and treatment efficacy in follicular lymphoma. <i>Haematologica</i> , 2018, 103, e364-e367.	1.7	10
48	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. <i>Blood Cancer Journal</i> , 2018, 8, 27.	2.8	10
49	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144.	2.0	47
50	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. <i>Blood</i> , 2018, 131, 226-235.	0.6	31
51	High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology. <i>Blood Advances</i> , 2018, 2, 2755-2765.	2.5	74
52	Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. <i>Blood</i> , 2018, 132, 2401-2405.	0.6	64
53	Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma. <i>Nature Communications</i> , 2018, 9, 4001.	5.8	102
54	A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. <i>Blood</i> , 2018, 132, 413-422.	0.6	89

#	ARTICLE	IF	CITATIONS
55	Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD. <i>Haematologica</i> , 2018, 103, e590-e593.	1.7	16
56	Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. <i>Blood</i> , 2018, 132, 1695-1702.	0.6	49
57	A multiprotein supercomplex controlling oncogenic signalling in lymphoma. <i>Nature</i> , 2018, 560, 387-391.	13.7	276
58	Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 998-998.	0.6	19
59	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1560-1560.	0.6	2
60	The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imidazole® Continuation (BIONIC) Study. <i>Blood</i> , 2018, 132, 1615-1615.	0.6	1
61	Molecular Features of Primary Central Nervous System Lymphoma in a Large Tissue Microarray. <i>Blood</i> , 2018, 132, 348-348.	0.6	1
62	The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL. <i>Blood</i> , 2018, 132, 921-921.	0.6	1
63	Results of real-time cell-of-origin subtype identification by gene expression profiling in patients with ABC-type diffuse large B-cell lymphoma in the phase III trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP (ROBUST).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7548-7548.	0.8	1
64	Single-Cell Profiling Reveals Distinct Tumor Subtypes and Their Associated T-Cell Environments in Follicular Lymphoma. <i>Blood</i> , 2018, 132, 1577-1577.	0.6	0
65	UBR5 Mutations in Mantle Cell Lymphoma Lead to Increased Proliferation through a Cyclin D1-Dependent Mechanism. <i>Blood</i> , 2018, 132, 2849-2849.	0.6	0
66	A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408. <i>Blood</i> , 2018, 132, 4157-4157.	0.6	0
67	Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell Lymphoma Lead to an Altered Gene Expression Profile and Changes in Tumor Microenvironment Composition. <i>Blood</i> , 2018, 132, 669-669.	0.6	1
68	Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 324-332.	0.6	32
69	Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. <i>Leukemia</i> , 2017, 31, 83-91.	3.3	87
70	Non-Hodgkin lymphoma. <i>Lancet, The</i> , 2017, 390, 298-310.	6.3	615
71	The Genetic Basis of Hepatosplenic T-cell Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 369-379.	7.7	163
72	Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2017, 102, e199-e202.	1.7	4

#	ARTICLE	IF	CITATIONS
73	Can histologic transformation of follicular lymphoma be predicted and prevented?. Blood, 2017, 130, 258-266.	0.6	52
74	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. Haematologica, 2017, 102, 1413-1423.	1.7	39
75	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. Journal of Experimental Medicine, 2017, 214, 1371-1386.	4.2	144
76	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncolmmunology, 2017, 6, e1321184.	2.1	23
77	Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases. British Journal of Haematology, 2017, 178, 442-447.	1.2	21
78	Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. Hematological Oncology, 2017, 35, 397-407.	0.8	11
79	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clinical Cancer Research, 2017, 23, 4127-4137.	3.2	135
80	Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood, 2017, 129, 2760-2770.	0.6	112
81	Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. Blood, 2017, 130, 1819-1831.	0.6	62
82	Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. Haematologica, 2017, 102, e404-e406.	1.7	16
83	Observation as the initial management strategy in patients with mantle cell lymphoma. Annals of Oncology, 2017, 28, 2489-2495.	0.6	67
84	Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. British Journal of Haematology, 2017, 176, 210-221.	1.2	78
85	CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer Discovery, 2017, 7, 38-53.	7.7	218
86	Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. British Journal of Haematology, 2017, 176, 234-240.	1.2	20
87	Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia, 2017, 31, 517-519.	3.3	14
88	Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. British Journal of Haematology, 2017, 179, 508-510.	1.2	26
89	Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 113-117.	1.4	5
90	Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Advances, 2017, 1, 2600-2609.	2.5	62

#	ARTICLE	IF	CITATIONS
91	New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. <i>Journal of Clinical Oncology</i> , 2017, 35, 1668-1677.	0.8	102
92	Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3722-3733.	0.8	48
93	Rapid, real-time central pathology review for E1412: A novel and successful paradigm for future National Clinical Trials Network diffuse large B cell lymphoma studies.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7547-7547.	0.8	1
94	Abstract 2445: Integrative genetic analysis identifies therapeutic relevance of cell of origin-specific genetic alterations in diffuse large B-cell lymphoma. , 2017, , .		0
95	9. The biology of primary mediastinal large B-cell lymphoma. , 2016, , 171-192.		0
96	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016, 12, 1553-1563.	1.1	85
97	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
98	CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2016, 34, 3150-3156.	0.8	313
99	Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia. <i>Journal of Clinical Oncology</i> , 2016, 34, 2493-2500.	0.8	56
100	Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. <i>British Journal of Haematology</i> , 2016, 173, 867-875.	1.2	36
101	General Biomarker Recommendations for Lymphoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw250.	3.0	2
102	Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000679.	0.5	3
103	Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2016, 29, 494-507.	7.7	93
104	Role of the tumor microenvironment in mature B-cell lymphoid malignancies. <i>Haematologica</i> , 2016, 101, 531-540.	1.7	75
105	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	0.8	239
106	Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. <i>Blood</i> , 2016, 127, 2182-2188.	0.6	145
107	Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas. <i>Blood</i> , 2016, 128, 1206-1213.	0.6	47
108	Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. <i>Blood</i> , 2016, 128, 1112-1120.	0.6	177

#	ARTICLE	IF	CITATIONS
109	Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. <i>Cell</i> , 2016, 167, 405-418.e13.	13.5	204
110	Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas. <i>Haematologica</i> , 2016, 101, e411-e414.	1.7	11
111	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology</i> , 2016, 3, e467-e479.	2.2	63
112	EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. <i>Cancer Cell</i> , 2016, 30, 197-213.	7.7	200
113	Impaired functional responses in follicular lymphoma CD8 ⁺ TIM-3 ⁺ T lymphocytes following TCR engagement. <i>OncImmunology</i> , 2016, 5, e1224044.	2.1	32
114	Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. <i>Blood</i> , 2016, 128, 1490-1502.	0.6	255
115	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. <i>Blood</i> , 2016, 127, 2203-2213.	0.6	68
116	Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). <i>Cancer</i> , 2016, 122, 2996-3004.	2.0	31
117	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2226-2236.	3.2	26
118	Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 872-879.	0.6	10
119	The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study. <i>Annals of Oncology</i> , 2016, 27, 1095-1099.	0.6	43
120	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 821-826.	3.2	26
121	Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. <i>Leukemia and Lymphoma</i> , 2016, 57, 717-720.	0.6	13
122	A Novel Prognostic Model Based on Tumor Microenvironment Biology in Relapse Biopsies Predicts Post-Autologous Stem Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1093-1093.	0.6	12
123	DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2686-2686.	0.6	1
124	Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial. <i>Blood</i> , 2016, 128, 2992-2992.	0.6	5
125	Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. <i>Blood</i> , 2016, 128, 4096-4096.	0.6	1
126	EFS24 as a predictor of outcome in a population-based cohort of patients with DLBCL in British Columbia (BC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7569-7569.	0.8	2

#	ARTICLE	IF	CITATIONS
127	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. PLoS Medicine, 2016, 13, e1002197.	3.9	185
128	Abstract IA18: Functional characterization of the tumor suppressor lysine-specific methyltransferase KMT2D in lymphoma. , 2016, , .		0
129	Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.. Journal of Clinical Oncology, 2016, 34, 7547-7547.	0.8	0
130	Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study. Blood, 2016, 128, 4145-4145.	0.6	0
131	Targeted Sequencing Reveals Novel Gene Mutations Associated with Transformation and Early Progression in Follicular Lymphoma. Blood, 2016, 128, 2919-2919.	0.6	5
132	Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. Blood, 2016, 128, 735-735.	0.6	0
133	Frequent Genetic Alterations of PI3K-AKT Pathway and Their Clinical Significance in Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 607-607.	0.6	1
134	Revealing the Tumor Ecosystem in Follicular Lymphoma By Mass Cytometry. Blood, 2016, 128, 2939-2939.	0.6	0
135	The Role of UBR5 Mutations in the Pathogenesis of Mantle CELL Lymphoma. Blood, 2016, 128, 4124-4124.	0.6	0
136	Divergent Modes of Tumor Evolution Underlie Histological Transformation and Early Progression of Follicular Lymphoma. Blood, 2016, 128, 1091-1091.	0.6	0
137	Characterization of Genomic Rearrangements Involving CIITA and SOCS1 Using Targeted Capture Sequencing of Archival Tissue Specimens. Blood, 2016, 128, 2925-2925.	0.6	0
138	Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target. Blood, 2016, 128, 4095-4095.	0.6	0
139	Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. Cell Reports, 2015, 13, 1418-1431.	2.9	112
140	An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. Blood, 2015, 125, 959-966.	0.6	24
141	IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. Blood, 2015, 126, 1741-1752.	0.6	184
142	Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood, 2015, 125, 1137-1145.	0.6	110
143	Genetic inactivation of TRAF3 in canine and human B-cell lymphoma. Blood, 2015, 125, 999-1005.	0.6	67
144	A roadmap for discovery and translation in lymphoma. Blood, 2015, 125, 2175-2177.	0.6	18

#	ARTICLE	IF	CITATIONS
145	Cell of origin of transformed follicular lymphoma. <i>Blood</i> , 2015, 126, 2118-2127.	0.6	91
146	Gray zone lymphoma with features intermediate between classical <sc>H</sc>odgkin lymphoma and diffuse large <sc>B</sc>â€cell lymphoma: <sc>C</sc>haracteristics, outcomes, and prognostication among a large multicenter cohort. <i>American Journal of Hematology</i> , 2015, 90, 778-783.	2.0	71
147	A phase <sc>II</sc> trial of <sc>RCHOP</sc> followed by radioimmunotherapy for early stage (stages I/<sc>II</sc>) diffuse large Bâ€cell nonâ€Hodgkin lymphoma: <sc>ECOG</sc> 3402. <i>British Journal of Haematology</i> , 2015, 170, 679-686.	1.2	19
148	Evaluation of the International Prognostic Score (IPSâ€7) and a Simpler Prognostic Score (IPSâ€3) for advanced Hodgkin lymphoma in the modern era. <i>British Journal of Haematology</i> , 2015, 171, 530-538.	1.2	54
149	Reply to M. Gleeson et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 3216-3217.	0.8	1
150	Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1322-1330.	2.1	63
151	Recurrent genomic rearrangements in primary testicular lymphoma. <i>Journal of Pathology</i> , 2015, 236, 136-141.	2.1	47
152	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv279.	3.0	152
153	XIV. The pathology of transformation of indolent B cell lymphomas. <i>Hematological Oncology</i> , 2015, 33, 75-79.	0.8	15
154	Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. <i>British Journal of Haematology</i> , 2015, 169, 415-422.	1.2	66
155	Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. <i>Blood</i> , 2015, 125, 22-32.	0.6	445
156	Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 341-348.	0.2	39
157	Anxiety and Health-Related Quality of Life Among Patients With Lowâ€Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). <i>Journal of Clinical Oncology</i> , 2015, 33, 740-748.	0.8	36
158	Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. <i>Genome Biology</i> , 2015, 16, 18.	3.8	107
159	Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. <i>Lancet Oncology, The</i> , 2015, 16, 1111-1122.	5.1	483
160	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. <i>Journal of Clinical Oncology</i> , 2015, 33, 2848-2856.	0.8	334
161	IL10 receptor is a novel therapeutic target in DLBCLs. <i>Leukemia</i> , 2015, 29, 1684-1694.	3.3	53
162	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1936-1942.	0.8	33

#	ARTICLE	IF	CITATIONS
163	Summary and Future Directions. <i>Seminars in Hematology</i> , 2015, 52, 143-147.	1.8	0
164	The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association. <i>Clinical Cancer Research</i> , 2015, 21, 3428-3435.	3.2	101
165	Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). <i>British Journal of Haematology</i> , 2015, 170, 56-65.	1.2	50
166	Tumor-associated macrophages in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2015, 100, 143-145.	1.7	51
167	Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. <i>British Journal of Haematology</i> , 2015, 169, 520-527.	1.2	58
168	Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 13447-13454.	3.3	143
169	Lifetime Physical Activity and the Risk of Non-Hodgkin Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 873-877.	1.1	11
170	Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. <i>Annals of Hematology</i> , 2015, 94, 1839-1843.	0.8	64
171	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. <i>Nature Medicine</i> , 2015, 21, 1199-1208.	15.2	359
172	High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma. <i>Oncogene</i> , 2015, 34, 1231-1240.	2.6	60
173	Bromodomain Inhibition in Diffuse Large B-cell Lymphoma—Giving MYC a Brake. <i>Clinical Cancer Research</i> , 2015, 21, 4-6.	3.2	19
174	Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 251-257.	0.8	319
175	Comprehensive MYC and BCL2 Genetic Profiling in De Novo Diffuse Large B-Cell Lymphoma Demonstrates Clinically Relevant Genetic Alterations According to Cell of Origin Subtype. <i>Blood</i> , 2015, 126, 109-109.	0.6	1
176	Outcome of Observation As Initial Strategy in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2015, 126, 2699-2699.	0.6	3
177	A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 333-333.	0.6	7
178	Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 571-571.	0.6	1
179	Whole Exome Sequencing of Type 1 and Type 2 Enteropathy-Associated T Cell Lymphoma Reveals Genetic Basis of EATL Oncogenesis. <i>Blood</i> , 2015, 126, 575-575.	0.6	3
180	Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation. <i>Blood</i> , 2015, 126, 579-579.	0.6	20

#	ARTICLE	IF	CITATIONS
181	What Will We Learn from Genomics and Proteomics in Hodgkin Lymphoma?. Hematologic Malignancies, 2015, , 79-92.	0.2	0
182	Abstract A19: MALT1 inhibition as an anchor for combinatorial therapy of ABC-DLBCL. , 2015, ,		0
183	Maintenance Rituximab Following R-CHOP Chemotherapy in Patients with Composite or Discordant, Indolent and Aggressive, B-Cell Non-Hodgkin Lymphomas. Blood, 2015, 126, 3950-3950.	0.6	0
184	A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas. Blood, 2015, 126, 434-434.	0.6	0
185	Mass Cytometry Based Classification of Inter- and Intra-Tumoral Heterogeneity in Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 3908-3908.	0.6	0
186	Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG) Tj ETQq0 0 0 rgBT. Overlook 10 Tf 50		
187	Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y90-Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499. Blood, 2015, 126, 2702-2702.	0.6	0
188	Flow Cytometric Characterization of 129 Cases of Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL NOS) and Angioimmunoblastic T Cell Lymphoma (AITL). Blood, 2015, 126, 2667-2667.	0.6	1
189	Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study. Blood, 2015, 126, 3971-3971.	0.6	0
190	Genetic Alterations of G \pm 13 Signaling Pathway with BCL2 over-Expression Confers Lymphoma Dissemination and Inferior Outcome in Germinal Center B Cell Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 111-111.	0.6	0
191	Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leukemia and Lymphoma, 2014, 55, 768-772.	0.6	42
192	Implementing a Multi-analyte Immunohistochemistry Panel into a Drug Development Program. Methods in Pharmacology and Toxicology, 2014, , 345-358.	0.1	0
193	Loss of signalling via G \pm 13 in germinal centre B-cell-derived lymphoma. Nature, 2014, 516, 254-258.	13.7	253
194	Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. Leukemia, 2014, 28, 362-372.	3.3	27
195	Rituximab Extended Schedule or Re-Treatment Trial for Low-Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402. Journal of Clinical Oncology, 2014, 32, 3096-3102.	0.8	159
196	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas. American Journal of Surgical Pathology, 2014, 38, 768-775.	2.1	44
197	FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma. Blood, 2014, 124, 3118-3129.	0.6	35
198	Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood, 2014, 123, 2062-2065.	0.6	259

#	ARTICLE	IF	CITATIONS
199	The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. <i>Annals of Oncology</i> , 2014, 25, 669-674.	0.6	40
200	Pharmacological and genomic profiling identifies NF- κ B-targeted treatment strategies for mantle cell lymphoma. <i>Nature Medicine</i> , 2014, 20, 87-92.	15.2	303
201	Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms. <i>Cancer Discovery</i> , 2014, 4, 480-493.	7.7	130
202	Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. <i>British Journal of Haematology</i> , 2014, 164, 896-899.	1.2	0
203	Duodenal follicular lymphoma: Comprehensive gene expression analysis with insights into pathogenesis. <i>Cancer Science</i> , 2014, 105, 608-615.	1.7	56
204	CD30 expression in <i>de novo</i> diffuse large B-cell lymphoma: a population-based study from British Columbia. <i>British Journal of Haematology</i> , 2014, 167, 608-617.	1.2	84
205	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 130-144.	0.9	265
206	Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. <i>Nature Genetics</i> , 2014, 46, 329-335.	9.4	180
207	An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>Blood</i> , 2014, 123, 837-842.	0.6	693
208	MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. <i>British Journal of Haematology</i> , 2014, 165, 382-391.	1.2	157
209	The tumour microenvironment in B cell lymphomas. <i>Nature Reviews Cancer</i> , 2014, 14, 517-534.	12.8	417
210	BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2014, 45, 2144-2153.	1.1	34
211	Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. <i>Blood</i> , 2014, 123, 1214-1217.	0.6	518
212	A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. <i>Blood</i> , 2014, 123, 3914-3924.	0.6	69
213	The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2014, 99, 715-725.	1.7	52
214	Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. <i>Blood</i> , 2014, 123, 1681-1690.	0.6	110
215	Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. <i>Blood</i> , 2014, 123, 1699-1708.	0.6	83
216	Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405). <i>Blood</i> , 2014, 123, 1665-1673.	0.6	61

#	ARTICLE	IF	CITATIONS
217	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , 2014, 123, 2915-2923.	0.6	435
218	Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. <i>Blood</i> , 2014, 123, 3567-3573.	0.6	76
219	Cell-of-Origin Assignment in Diffuse Large B-Cell Lymphoma Determined By Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry. <i>Blood</i> , 2014, 124, 1624-1624.	0.6	1
220	CD28 Mutations in Peripheral T-Cell Lymphomagenesis and Progression. <i>Blood</i> , 2014, 124, 1681-1681.	0.6	4
221	Single Cell Mass Cytometry for Phenotypic Analysis of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 2976-2976.	0.6	1
222	Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues. <i>Blood</i> , 2014, 124, 3016-3016.	0.6	10
223	FAS Mutations Accelerate Lymphoma Growth and Induce Therapeutic Resistance. <i>Blood</i> , 2014, 124, 3018-3018.	0.6	1
224	Outcome in Unselected Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Following R-CHOP When Stem Cell Transplantation Is Not Feasible. <i>Blood</i> , 2014, 124, 3069-3069.	0.6	8
225	IDH2 R172 Mutations Define a Unique Subgroup of Patients in Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2014, 124, 3580-3580.	0.6	3
226	Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). <i>Blood</i> , 2014, 124, 392-392.	0.6	23
227	Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 394-394.	0.6	27
228	The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014, 124, 495-495.	0.6	8
229	A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Relapsed/Refractory DLBCL. <i>Blood</i> , 2014, 124, 628-628.	0.6	18
230	Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2014, 124, 703-703.	0.6	5
231	A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL). <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8615-TPS8615.	0.8	9
232	Abstract SY09-03: How deregulation of histone methyltransferases drive malignant transformation of B-cells. , 2014, , .		0
233	Abstract 2945: Characterization of a novel protein-coding gene named TIHL (Translocated in Hodgkin's) Tj ETQq1 1 0.784314 rgBT /Ove		
234	Analysis of Relapse Biopsies in Classical Hodgkin Lymphoma Reveals Correlations with Outcome after Autologous Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 136-136.	0.6	0

#	ARTICLE	IF	CITATIONS
235	Chemical Genomics Reveals JAK STAT Activation As a Mechanism of Resistance to HDAC Inhibitors in B Cell Lymphomas. <i>Blood</i> , 2014, 124, 271-271.	0.6	1
236	Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. <i>Blood</i> , 2014, 124, 1703-1703.	0.6	0
237	Genetic Alterations of the MHC Class II Transactivator CIITA Are Frequent in Primary Mediastinal Large B-Cell Lymphoma and Associated with Diminished MHC Class II Expression. <i>Blood</i> , 2014, 124, 3040-3040.	0.6	0
238	Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. <i>Blood</i> , 2014, 124, 1667-1667.	0.6	0
239	Primary Cutaneous Anaplastic Large Cell Lymphoma: The British Columbia Cancer Agency Experience. <i>Blood</i> , 2014, 124, 3076-3076.	0.6	0
240	Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype. <i>International Journal of Cancer</i> , 2013, 133, n/a-n/a.	2.3	26
241	Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2013, 31, 4520-4528.	0.8	113
242	Newly Identified Mechanisms in B-Cell Non-Hodgkin Lymphomas Uncovered by Next-Generation Sequencing. <i>Seminars in Hematology</i> , 2013, 50, 303-313.	1.8	17
243	MicroRNA Signature Obtained From the Comparison of Aggressive With Indolent Non-Hodgkin Lymphomas: Potential Prognostic Value in Mantle-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2903-2911.	0.8	37
244	Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 692-700.	0.8	176
245	Lymphotoxin network pathways shape the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2013, 25, 222-229.	2.4	25
246	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	0.6	596
247	Controversies in BMT for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S26-S32.	2.0	4
248	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013, 31, 684-691.	0.8	256
249	Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. <i>Blood</i> , 2013, 121, 3666-3674.	0.6	139
250	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. <i>British Journal of Haematology</i> , 2013, 161, 76-86.	1.2	111
251	Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. <i>International Journal of Cancer</i> , 2013, 133, 2852-2863.	2.3	15
252	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. <i>Cancer Cell</i> , 2013, 23, 677-692.	7.7	706

#	ARTICLE	IF	CITATIONS
253	EZH2 mutations are frequent and represent an early event in follicular lymphoma. <i>Blood</i> , 2013, 122, 3165-3168.	0.6	274
254	Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma. <i>Cancer Discovery</i> , 2013, 3, 1002-1019.	7.7	180
255	Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. <i>PLoS Genetics</i> , 2013, 9, e1003137.	1.5	102
256	Related F-box proteins control cell death in <i>Caenorhabditis elegans</i> and human lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 3943-3948.	3.3	57
257	Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. <i>Annals of Oncology</i> , 2013, 24, 428-432.	0.6	36
258	Next-generation Sequencing Discoveries in Lymphoma. <i>Advances in Anatomic Pathology</i> , 2013, 20, 110-116.	2.4	15
259	Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors. <i>Journal of Clinical Oncology</i> , 2013, 31, 1970-1976.	0.8	335
260	Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating With Increased Copy Number, mRNA, and Protein in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2013, 139, 242-254.	0.4	29
261	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. <i>Blood</i> , 2013, 121, 3547-3553.	0.6	117
262	The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. <i>Blood</i> , 2013, 121, 3161-3164.	0.6	124
263	Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. <i>Blood</i> , 2013, 122, 1256-1265.	0.6	349
264	Sex- and Subtype-Specific Analysis of H2AFX Polymorphisms in Non-Hodgkin Lymphoma. <i>PLoS ONE</i> , 2013, 8, e74619.	1.1	1
265	Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma - Endpoints of a Spectrum of One Disease?. <i>PLoS ONE</i> , 2013, 8, e78812.	1.1	99
266	EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. <i>Blood</i> , 2013, 122, 1-1.	0.6	23
267	Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia. <i>Blood</i> , 2013, 122, 1788-1788.	0.6	5
268	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. <i>Blood</i> , 2013, 122, 3060-3060.	0.6	5
269	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013, 122, 4277-4277.	0.6	3
270	Gemcitabine, Dexamethasone, and Cisplatin (GDP) As Secondary Chemotherapy In Relapsed/Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4345-4345.	0.6	5

#	ARTICLE	IF	CITATIONS
271	Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma. <i>Blood</i> , 2013, 122, 507-507.	0.6	5
272	Genomic Rearrangements Involving Programmed Death Ligands Are Recurrent In Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 635-635.	0.6	3
273	Non-Hodgkin Lymphoma Risk and Variants in Genes Controlling Lymphocyte Development. <i>PLoS ONE</i> , 2013, 8, e75170.	1.1	10
274	Characterization Of The Effects Of Mutated EZH2 On Expression and Epigenome In a Mouse Lymphoma Model. <i>Blood</i> , 2013, 122, 346-346.	0.6	0
275	Predicting Cell Of Origin In Diffuse Large B-Cell Lymphoma By High Dimensional Flow Cytometry. <i>Blood</i> , 2013, 122, 4301-4301.	0.6	0
276	Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival. <i>Blood</i> , 2013, 122, 500-500.	0.6	0
277	Outcomes In Splenic Marginal Zone Lymphoma: Analysis Of 108 Patients Treated In British Columbia (BC). <i>Blood</i> , 2013, 122, 4369-4369.	0.6	0
278	The Outcome Of Patients With Post Transplant and Immunodeficiency Associated Lymphoproliferative Disorder: The BCCA Experience. <i>Blood</i> , 2013, 122, 4390-4390.	0.6	0
279	Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma. <i>Blood</i> , 2013, 122, 4232-4232.	0.6	0
280	Molecular and Functional Characterization Of The Novel Protein-Coding Gene Tihl (Translocated in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.6	0
281	Impact of Time from Diagnosis to Initiation of Curative-Intent Chemotherapy on Clinical Outcomes in Patients with Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 4237-4237.	0.6	3
282	Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue â€“ An L.L.M.P.P. Project. <i>Blood</i> , 2013, 122, 73-73.	0.6	0
283	Protein Tyrosine Phosphatase Type-1 (PTPN1) Is Frequently Mutated In Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 242-242.	0.6	1
284	Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe dâ€™Etude De Lymphome dâ€™Adultes. <i>Blood</i> , 2013, 122, 3045-3045.	0.6	2
285	The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas. <i>Blood</i> , 2013, 122, 1804-1804.	0.6	0
286	Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era. <i>Blood</i> , 2013, 122, 847-847.	0.6	2
287	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3452-3459.	0.8	824
288	Phase II Study of Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Immunochemotherapy Followed by Yttrium-90â€™Ibritumomab Tiuxetan in Untreated Mantle-Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. <i>Journal of Clinical Oncology</i> , 2012, 30, 3119-3126.	0.8	86

#	ARTICLE	IF	CITATIONS
289	Automated Analysis of Multidimensional Flow Cytometry Data Improves Diagnostic Accuracy Between Mantle Cell Lymphoma and Small Lymphocytic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2012, 137, 75-85.	0.4	36
290	International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era. <i>Journal of Clinical Oncology</i> , 2012, 30, 3383-3388.	0.8	171
291	Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. <i>Blood</i> , 2012, 120, 3530-3540.	0.6	122
292	Pathogenesis of follicular lymphoma. <i>Journal of Clinical Investigation</i> , 2012, 122, 3424-3431.	3.9	264
293	Reply to L. Wannesson et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 336-337.	0.8	0
294	FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 3503-3511.	0.6	149
295	SNP Analysis of Minimally Evolved t(14;18)(q32;q21)-Positive Follicular Lymphomas Reveals a Common Copy-Neutral Loss of Heterozygosity Pattern. <i>Cytogenetic and Genome Research</i> , 2012, 136, 38-43.	0.6	7
296	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. <i>Blood</i> , 2012, 119, 1963-1971.	0.6	313
297	A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. <i>Blood</i> , 2012, 119, 5118-5125.	0.6	145
298	TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 4949-4952.	0.6	60
299	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. <i>Blood</i> , 2012, 120, 3280-3287.	0.6	188
300	MYD88 somatic mutations in MALT lymphomas. <i>British Journal of Haematology</i> , 2012, 158, 662-664.	1.2	41
301	B Cells With High Side Scatter Parameter by Flow Cytometry Correlate With Inferior Survival in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2012, 137, 805-814.	0.4	12
302	MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo. <i>Cancer Cell</i> , 2012, 22, 812-824.	7.7	229
303	Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. <i>Blood</i> , 2012, 119, 3757-3766.	0.6	72
304	A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2012, 120, 2290-2296.	0.6	53
305	Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. <i>Blood</i> , 2012, 120, 4635-4644.	0.6	83
306	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. <i>Nature</i> , 2012, 490, 116-120.	13.7	759

#	ARTICLE	IF	CITATIONS
307	Recurrent targets of aberrant somatic hypermutation in lymphoma. <i>Oncotarget</i> , 2012, 3, 1308-1319.	0.8	127
308	Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. <i>Blood</i> , 2012, 119, 4939-4948.	0.6	97
309	BCL2 mutations in diffuse large B-cell lymphoma. <i>Leukemia</i> , 2012, 26, 1383-1390.	3.3	135
310	Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy. <i>Cancer</i> , 2012, 118, 4156-4165.	2.0	49
311	CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma. <i>Cytometry Part B - Clinical Cytometry</i> , 2012, 82B, 112-119.	0.7	20
312	Diffuse Aggressive B-Cell Lymphomas. , 2012, , 261-292.		1
313	Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2012, 120, 153-153.	0.6	9
314	The Outcome of Advanced Stage Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Compared to Classical Hodgkin's Lymphoma (CHL): A Matched Pair Analysis. <i>Blood</i> , 2012, 120, 1531-1531.	0.6	6
315	CD30 Expression in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1558-1558.	0.6	5
316	CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial. <i>Blood</i> , 2012, 120, 1638-1638.	0.6	20
317	A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).. <i>Blood</i> , 2012, 120, 2687-2687.	0.6	2
318	The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era. <i>Blood</i> , 2012, 120, 303-303.	0.6	29
319	Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404). <i>Blood</i> , 2012, 120, 687-687.	0.6	4
320	Genetic Variation in Cell Death Genes and Risk of Non-Hodgkin Lymphoma. <i>PLoS ONE</i> , 2012, 7, e31560.	1.1	21
321	Mutations of STAT6 DNA Binding Domain Are Characteristic of PMBL and Belong to the Genetic Signature of This Entity.. <i>Blood</i> , 2012, 120, 2645-2645.	0.6	0
322	High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. <i>Blood</i> , 2012, 120, 545-545.	0.6	0
323	A 7-Gene Microrna Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis. <i>Blood</i> , 2012, 120, 1586-1586.	0.6	0
324	Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2012, 120, 235-235.	0.6	0

#	ARTICLE	IF	CITATIONS
325	Population Survey of Mantle Cell Lymphoma (MCL) in British Columbia (BC) – A Heterogeneous Disorder with Improved Outcomes in the Modern Era. <i>Blood</i> , 2012, 120, 1602-1602.	0.6	0
326	SOX11 Directly Represses Wnt/ β 2-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment. <i>Blood</i> , 2012, 120, 895-895.	0.6	2
327	Identification of a Novel Protein-Coding Gene (TIHL) and Its Functional Relevance in Myeloid Cells.. <i>Blood</i> , 2012, 120, 2333-2333.	0.6	0
328	FAS Mutations Are Associated with Therapeutic Resistance in Follicular Lymphoma. <i>Blood</i> , 2012, 120, 1549-1549.	0.6	0
329	Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma.. <i>Blood</i> , 2012, 120, 2648-2648.	0.6	0
330	Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab. <i>Blood</i> , 2012, 120, 3705-3705.	0.6	0
331	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. <i>Blood</i> , 2012, 120, 1545-1545.	0.6	6
332	Tumor-Associated Macrophages Predict Outcome in Follicular Lymphoma. <i>Blood</i> , 2012, 120, 682-682.	0.6	4
333	Large-Scale High Resolution Integration of Copy Number and Gene Expression in DLBCL Reveals Focal and Frequent Deletions in Chromatin Modifying Genes with Outcome Correlation. <i>Blood</i> , 2012, 120, 295-295.	0.6	0
334	Next-Generation Sequencing of Lymphoid Cancers: From Discovery to Clinical Translation. <i>Blood</i> , 2012, 120, SCI-12-SCI-12.	0.6	0
335	Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. <i>Leukemia and Lymphoma</i> , 2011, 52, 24-33.	0.6	22
336	Macrophages predict treatment outcome in Hodgkin's lymphoma. <i>Haematologica</i> , 2011, 96, 186-189.	1.7	50
337	Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome. <i>Blood</i> , 2011, 118, 4585-4590.	0.6	83
338	Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment. <i>Journal of Clinical Oncology</i> , 2011, 29, 1812-1826.	0.8	350
339	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. <i>Nature</i> , 2011, 476, 298-303.	13.7	1,428
340	Transformation of follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 147-163.	0.7	142
341	Molecular Characteristics of Mantle Cell Lymphoma Presenting With Clonal Plasma Cell Component. <i>American Journal of Surgical Pathology</i> , 2011, 35, 177-189.	2.1	23
342	MYC and Aggressive B-cell Lymphomas. <i>Advances in Anatomic Pathology</i> , 2011, 18, 219-228.	2.4	129

#	ARTICLE	IF	CITATIONS
343	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	0.6	173
344	Peripheral T-cell lymphoma. <i>Blood</i> , 2011, 117, 6756-6767.	0.6	278
345	Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. <i>Blood</i> , 2011, 117, 2451-2459.	0.6	556
346	Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. <i>Blood</i> , 2011, 118, 148-155.	0.6	308
347	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. <i>Blood</i> , 2011, 117, 7070-7078.	0.6	168
348	The molecular pathogenesis of primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2011, 118, 2659-2669.	0.6	189
349	MicroRNA profiles of t(14;18) ⁻ negative follicular lymphoma support a late germinal center B-cell phenotype. <i>Blood</i> , 2011, 118, 5550-5558.	0.6	77
350	Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. <i>Haematologica</i> , 2011, 96, 1002-1007.	1.7	69
351	High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. <i>Haematologica</i> , 2011, 96, 996-1001.	1.7	100
352	Genomic profiles of MALT lymphomas: variability across anatomical sites. <i>Haematologica</i> , 2011, 96, 1064-1066.	1.7	42
353	Oncogenically active MYD88 mutations in human lymphoma. <i>Nature</i> , 2011, 470, 115-119.	13.7	1,292
354	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. <i>Nature</i> , 2011, 471, 377-381.	13.7	551
355	Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. <i>Blood</i> , 2011, 118, 1350-1358.	0.6	175
356	Loss of BAF250a (<i>ARID1A</i>) is frequent in high-grade endometrial carcinomas. <i>Journal of Pathology</i> , 2011, 224, 328-333.	2.1	210
357	VII. The role of the microenvironment in lymphoid cancers. <i>Annals of Oncology</i> , 2011, 22, iv47-iv50.	0.6	6
358	Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. <i>Annals of Oncology</i> , 2011, 22, 1164-1169.	0.6	57
359	The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. <i>American Journal of Clinical Pathology</i> , 2011, 135, 54-61.	0.4	71
360	MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. <i>Clinical Cancer Research</i> , 2011, 17, 4125-4135.	3.2	126

#	ARTICLE	IF	CITATIONS
361	Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. <i>Journal of Clinical Oncology</i> , 2011, 29, 200-207.	0.8	426
362	Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues. <i>Clinical Cancer Research</i> , 2011, 17, 3727-3732.	3.2	68
363	Impact of Concordant and Discordant Bone Marrow Involvement on Outcome in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2011, 29, 1452-1457.	0.8	197
364	BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab. <i>Clinical Cancer Research</i> , 2011, 17, 7785-7795.	3.2	152
365	Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. <i>Blood</i> , 2011, 117, 3402-3408.	0.6	376
366	Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. <i>Modern Pathology</i> , 2011, 24, 1586-1597.	2.9	137
367	Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 3396-3401.	0.8	33
368	Burkitt's Lymphoma. , 2011, , 391-409.		2
369	Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. <i>Blood</i> , 2011, 118, 1603-1603.	0.6	3
370	Mutated EZH2 Collaborates with Myc in Inducing Lymphoma in a Mouse Model. <i>Blood</i> , 2011, 118, 227-227.	0.6	3
371	A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial. <i>Blood</i> , 2011, 118, 430-430.	0.6	1
372	Diffuse Large B-Cell Lymphoma with Testicular Involvement: Outcome and Risk of CNS Relapse in the Rituximab Era. <i>Blood</i> , 2011, 118, 780-780.	0.6	3
373	Survival of Peripheral T-Cell Lymphomas (PTCLs) Patients Following Relapse: Spectrum of Disease and Rare Long-Term Survivors. <i>Blood</i> , 2011, 118, 96-96.	0.6	2
374	CSF1R Expression of Hodgkin Reed Sternberg Cells Is Associated with the Number of Macrophages in the Tumor Microenvironment and Is Correlated with Treatment Outcome. <i>Blood</i> , 2011, 118, 427-427.	0.6	0
375	Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas. <i>Blood</i> , 2011, 118, 435-435.	0.6	0
376	Gene Risk Scores Based on Expression of 6 Genes Quantitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study. <i>Blood</i> , 2011, 118, 87-87.	0.6	1
377	Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis. <i>Blood</i> , 2011, 118, 556-556.	0.6	0
378	High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma. <i>Blood</i> , 2011, 118, 585-585.	0.6	0

#	ARTICLE	IF	CITATIONS
379	Inactivating Gene Alterations of MHC Class II Transactivator CIITA Are Recurrent in Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 437-437.	0.6	4
380	Vascularization predicts overall survival and risk of transformation in follicular lymphoma. <i>Haematologica</i> , 2010, 95, 2157-2160.	1.7	44
381	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. <i>Haematologica</i> , 2010, 95, 96-101.	1.7	63
382	The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. <i>Blood</i> , 2010, 115, 289-295.	0.6	173
383	Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. <i>Blood</i> , 2010, 115, 775-777.	0.6	117
384	Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. <i>Blood</i> , 2010, 116, 418-427.	0.6	152
385	Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. <i>Blood</i> , 2010, 116, 953-961.	0.6	122
386	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. <i>Blood</i> , 2010, 116, 5247-5255.	0.6	262
387	DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2010, 116, e81-e89.	0.6	138
388	Elevated circulating t(14;18) translocation levels prior to diagnosis of follicular lymphoma. <i>Blood</i> , 2010, 116, 6146-6147.	0.6	17
389	The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. <i>Haematologica</i> , 2010, 95, 2056-2062.	1.7	28
390	Immunoexpression of Survivin in non-neoplastic lymphoid tissues and malignant lymphomas using a new monoclonal antibody reactive on paraffin sections. <i>Journal of Hematopathology</i> , 2010, 3, 3-9.	0.2	4
391	Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2010, 21, 11-22.	0.8	36
392	Cooperative Epigenetic Modulation by Cancer Amplicon Genes. <i>Cancer Cell</i> , 2010, 18, 590-605.	7.7	263
393	High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 669-681.	1.5	51
394	Long-term outcomes for patients with limited stage follicular lymphoma. <i>Cancer</i> , 2010, 116, 3797-3806.	2.0	94
395	GBV β /hepatitis G virus infection and non-Hodgkin lymphoma: a case control study. <i>International Journal of Cancer</i> , 2010, 126, 2885-2892.	2.3	51
396	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). <i>British Journal of Haematology</i> , 2010, 148, 235-244.	1.2	38

#	ARTICLE	IF	CITATIONS
397	Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-PI). <i>British Journal of Haematology</i> , 2010, 151, 143-151.	1.2	85
398	Selective ablation of the YxxM motif of IL-7R α suppresses lymphomagenesis but maintains lymphocyte development. <i>Oncogene</i> , 2010, 29, 3854-3864.	2.6	15
399	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. <i>Nature</i> , 2010, 463, 88-92.	13.7	1,402
400	Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. <i>Nature Genetics</i> , 2010, 42, 181-185.	9.4	1,504
401	HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. <i>Nature Immunology</i> , 2010, 11, 265-272.	7.0	196
402	Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. <i>Annals of Oncology</i> , 2010, 21, 1046-1052.	0.6	182
403	Acquired TNFRSF14 Mutations in Follicular Lymphoma Are Associated with Worse Prognosis. <i>Cancer Research</i> , 2010, 70, 9166-9174.	0.4	160
404	Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494. <i>Clinical Cancer Research</i> , 2010, 16, 2435-2442.	3.2	25
405	Hypoxia-Inducible Factor-1 α Expression Predicts Superior Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. <i>Journal of Clinical Oncology</i> , 2010, 28, 1017-1024.	0.8	57
406	Prognostic biomarkers in malignant lymphomas. <i>Leukemia and Lymphoma</i> , 2010, 51, 11-19.	0.6	21
407	Lymphoma stem cells: enough evidence to support their existence?. <i>Haematologica</i> , 2010, 95, 293-302.	1.7	57
408	Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B). <i>Molecular Cancer</i> , 2010, 9, 14.	7.9	14
409	A Novel Method of Amplification of FFPET-Derived RNA Enables Accurate Disease Classification with Microarrays. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 680-686.	1.2	51
410	Transformation to Aggressive Lymphoma in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 793-799.	0.8	178
411	Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 362, 875-885.	13.9	1,141
412	Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. <i>Cell</i> , 2010, 142, 699-713.	13.5	894
413	Prognostic Factors in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 2902-2913.	0.8	136
414	Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. <i>Leukemia and Lymphoma</i> , 2010, 51, 1-10.	0.6	53

#	ARTICLE	IF	CITATIONS
415	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. <i>Journal of Clinical Investigation</i> , 2010, 120, 4569-4582.	3.9	101
416	Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL). <i>Blood</i> , 2010, 116, 113-113.	0.6	16
417	Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment. <i>Blood</i> , 2010, 116, 1751-1751.	0.6	4
418	Incorporation of ABVD Increases Cure Rates of Patients with Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL). <i>Blood</i> , 2010, 116, 3887-3887.	0.6	2
419	A Randomized Phase III Trial of ABVD Vs. Stanford V +/â” Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Blood</i> , 2010, 116, 415-415.	0.6	18
420	Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496. <i>Blood</i> , 2010, 116, 416-416.	0.6	8
421	Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials. <i>Blood</i> , 2010, 116, 417-417.	0.6	2
422	Mutations In MLL2 and MEF2B Genes In Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 473-473.	0.6	6
423	Identification of Genes Frequently Mutated In FL and DLBCL with Transcriptome, Genome and Exome Sequencing. <i>Blood</i> , 2010, 116, 804-804.	0.6	1
424	FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP. <i>Blood</i> , 2010, 116, 854-854.	0.6	9
425	Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2010, 116, 2005-2005.	0.6	2
426	The Prognosis of Limited Stage Peripheral T-Cell Lymphoma (PTCL): A Population-Based Analysis and Comparison to Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2010, 116, 4129-4129.	0.6	0
427	Comparing MicroRNA Expression In Aggressive and Indolent Non-Hodgkin Lymphomas Identifies a Prognostic Signature for Mantle Cell Lymphoma. <i>Blood</i> , 2010, 116, 800-800.	0.6	0
428	Recurrent DNA Mutations In Non-Hodgkin Lymphomas Reveal Candidate Therapeutic Targets. <i>Blood</i> , 2010, 116, 632-632.	0.6	0
429	Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance. <i>Blood</i> , 2010, 116, 1803-1803.	0.6	0
430	Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. <i>Blood</i> , 2010, 116, 2006-2006.	0.6	0
431	BCL2 Is Highly Mutated In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 4187-4187.	0.6	0
432	CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. <i>Haematologica</i> , 2009, 94, 596-598.	1.7	18

#	ARTICLE	IF	CITATIONS
433	Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1607-1614.	0.8	264
434	Model-based clustering of array CGH data. <i>Bioinformatics</i> , 2009, 25, i30-i38.	1.8	17
435	The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-cell Lymphoma Project. <i>Annals of Oncology</i> , 2009, 20, 715-721.	0.6	56
436	Anaplastic Lymphoma Kinase-Positive Diffuse Large B-Cell Lymphoma: A Rare Clinicopathologic Entity With Poor Prognosis. <i>Journal of Clinical Oncology</i> , 2009, 27, 4211-4216.	0.8	154
437	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. <i>Haematologica</i> , 2009, 94, 1555-1562.	1.7	345
438	Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. <i>BMC Medical Genetics</i> , 2009, 10, 117.	2.1	27
439	The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. <i>British Journal of Haematology</i> , 2009, 146, 257-269.	1.2	56
440	Array-based DNA methylation profiling in follicular lymphoma. <i>Leukemia</i> , 2009, 23, 1858-1866.	3.3	65
441	Atypical Lymphoid Hyperplasia Mimicking Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 729-745.	0.9	43
442	Preface. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, xi-xii.	0.9	0
443	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. <i>Blood</i> , 2009, 114, 3533-3537.	0.6	566
444	Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. <i>Blood</i> , 2009, 114, 826-834.	0.6	177
445	Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. <i>Leukemia and Lymphoma</i> , 2009, 50, 1875-1878.	0.6	9
446	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. <i>Blood</i> , 2009, 114, 2273-2279.	0.6	523
447	A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. <i>Clinical Cancer Research</i> , 2009, 15, 5494-5502.	3.2	577
448	Circos: An information aesthetic for comparative genomics. <i>Genome Research</i> , 2009, 19, 1639-1645.	2.4	9,003
449	9202 Long-term outcomes for patients with limited stage, follicular lymphoma: involved regional radiotherapy versus involved nodal radiotherapy. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 560-561.	2.2	0
450	Follicular Lymphoma of the Thyroid Gland. <i>American Journal of Surgical Pathology</i> , 2009, 33, 22-34.	2.1	43

#	ARTICLE	IF	CITATIONS
451	CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. <i>Haematologica</i> , 2009, 94, 423-427.	1.7	53
452	Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. <i>Blood</i> , 2009, 113, 137-148.	0.6	122
453	Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. <i>Blood</i> , 2009, 113, 2298-2301.	0.6	75
454	Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. <i>Blood</i> , 2009, 113, 3773-3780.	0.6	133
455	Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. <i>Blood</i> , 2009, 113, 3754-3764.	0.6	226
456	The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. <i>Blood</i> , 2009, 113, 5536-5548.	0.6	205
457	Stem cells in Hodgkin lymphoma?. <i>Blood</i> , 2009, 113, 5694-5694.	0.6	3
458	HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy.. <i>Blood</i> , 2009, 114, 133-133.	0.6	3
459	Tyrosine 641 of the EZH2 Oncogene Is Frequently Mutated in Follicular and Diffuse Large B-Cell Lymphomas of Germinal Center Origin.. <i>Blood</i> , 2009, 114, 139-139.	0.6	3
460	The International Prognostic Factor Project Score (IPS) in Advanced Stage Hodgkin Lymphoma Has Limited Utility in Patients Treated in the Modern Era.. <i>Blood</i> , 2009, 114, 1554-1554.	0.6	4
461	The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 - A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.. <i>Blood</i> , 2009, 114, 1661-1661.	0.6	9
462	A Comparison of Gene Expression Pattern in Major Histocompatibility Class II-Low Diffuse Large B-Cell Lymphoma with Plasmablastic Lymphoma.. <i>Blood</i> , 2009, 114, 1941-1941.	0.6	1
463	The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.. <i>Blood</i> , 2009, 114, 2923-2923.	0.6	1
464	Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2009, 114, 3944-3944.	0.6	2
465	R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.. <i>Blood</i> , 2009, 114, 408-408.	0.6	28
466	Base-Pair Resolution of Somatic and Germline-Derived Genome Rearrangement Breakpoints in Follicular Lymphoma.. <i>Blood</i> , 2009, 114, 439-439.	0.6	0
467	Gene Expression Profiling of Microdissected Hodgkin Reed Sternberg Cells: Molecular Subtypes and Treatment Outcome Correlations.. <i>Blood</i> , 2009, 114, 268-268.	0.6	12
468	Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project.. <i>Blood</i> , 2009, 114, 620-620.	0.6	0

#	ARTICLE	IF	CITATIONS
469	MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 624-624.	0.6	0
470	TNFRSF14 Is Mutated in a Subset of Follicular Lymphoma and Correlated with Inferior Prognosis.. Blood, 2009, 114, 1919-1919.	0.6	1
471	Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions.. Blood, 2009, 114, 622-622.	0.6	2
472	MYC Translocations and Expression Are Clinically Important in R-CHOP Treated Patients with De Novo DLBCL.. Blood, 2009, 114, 1100-1100.	0.6	0
473	FAS Mutations in Follicular Lymphoma Are Rare but Associated with Aggressive Clinical Behavior.. Blood, 2009, 114, 3967-3967.	0.6	0
474	Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL).. Blood, 2009, 114, 2922-2922.	0.6	0
475	ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures.. Blood, 2009, 114, 619-619.	0.6	10
476	Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group.. Blood, 2009, 114, 407-407.	0.6	1
477	High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).. Blood, 2009, 114, 1948-1948.	0.6	0
478	Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada. International Journal of Cancer, 2008, 122, 630-633.	2.3	27
479	Prognostic significance of secondary cytogenetic alterations in follicular lymphomas. Genes Chromosomes and Cancer, 2008, 47, 1038-1048.	1.5	50
480	Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplantation, 2008, 42, 601-608.	1.3	21
481	Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. British Journal of Haematology, 2008, 140, 516-526.	1.2	145
482	Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. British Journal of Haematology, 2008, 141, 461-469.	1.2	100
483	Constitutive overexpression of a novel 21 kDa protein by Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphomas. Molecular Cancer, 2008, 7, 12.	7.9	6
484	Oncogenic <i>CARD11</i> Mutations in Human Diffuse Large B Cell Lymphoma. Science, 2008, 319, 1676-1679.	6.0	784
485	Classification of Non-Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America, 2008, 22, 781-805.	0.9	20
486	Involved-Nodal Radiation Therapy As a Component of Combination Therapy for Limited-Stage Hodgkin's Lymphoma: A Question of Field Size. Journal of Clinical Oncology, 2008, 26, 5170-5174.	0.8	126

#	ARTICLE	IF	CITATIONS
487	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13520-13525.	3.3	868
488	Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 2008, 26, 5165-5169.	0.8	333
489	Impact of whole genome amplification on analysis of copy number variants. Nucleic Acids Research, 2008, 36, e80-e80.	6.5	74
490	Stromal Gene Signatures in Large-B-Cell Lymphomas. New England Journal of Medicine, 2008, 359, 2313-2323.	13.9	1,564
491	Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas. Cancer Research, 2008, 68, 3361-3369.	0.4	30
492	Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor- κ B, p53, bax, and p27 levels. Molecular Cancer Therapeutics, 2008, 7, 749-758.	1.9	42
493	Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica, 2008, 93, 1327-1334.	1.7	80
494	LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab. Journal of Clinical Oncology, 2008, 26, 447-454.	0.8	159
495	Gene expression signatures in follicular lymphoma: are they ready for the clinic?. Haematologica, 2008, 93, 982-987.	1.7	6
496	Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor- κ B pathways in subtypes of diffuse large B-cell lymphoma. Blood, 2008, 111, 3701-3713.	0.6	315
497	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood, 2008, 112, 3088-3098.	0.6	173
498	ALK ⁻ anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK ⁺ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood, 2008, 111, 5496-5504.	0.6	784
499	Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood, 2008, 111, 5509-5514.	0.6	93
500	Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2008, 112, 3425-3433.	0.6	130
501	The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood, 2008, 112, 3126-3129.	0.6	112
502	Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCT.. Blood, 2008, 112, 2173-2173.	0.6	1
503	Interim Positron Emission Tomography (PET) in Diffuse Large B-Cell Lymphoma: Independent Expert Nuclear Medicine Evaluation of ECOG 3404. Blood, 2008, 112, 372-372.	0.6	3
504	Follicular Non-Hodgkin Lymphoma Grade 3a and 3b Subtypes Exhibit Similar Clinical Behaviour and Treatment Outcome. Blood, 2008, 112, 3777-3777.	0.6	5

#	ARTICLE	IF	CITATIONS
505	Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma. <i>Blood</i> , 2008, 112, 4459-4459.	0.6	8
506	Deletion in Chromosome 17p12 and Gains in Chromosome 9q33.3 by Array Comparative Hybridization Are Associated with R-CHOP Treatment Failure in Patients with Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2008, 112, 477-477.	0.6	2
507	Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP. <i>Blood</i> , 2008, 112, 479-479.	0.6	2
508	Array-CGH Identifies Both Common and Subtype-Specific Genomic Aberrations in Marginal Zone Lymphomas. <i>Blood</i> , 2008, 112, 622-622.	0.6	1
509	The Voltage-Gated Proton Channel HVCN1 Co-Localizes with B Cell Receptor and Is Involved in Class Switch Recombination in Vivo. <i>Blood</i> , 2008, 112, 707-707.	0.6	4
510	Salvage Therapy with Allogeneic Stem Cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared to Those with Transformed Non-Hodgkin Lymphoma: A Population-Based Comparative Study.. <i>Blood</i> , 2008, 112, 975-975.	0.6	29
511	Loss of CIITA and MHC Class II Expression in Diffuse Large B-Cell Lymphoma Is Not Explained by Methylation of CIITA Promoters III and IV.. <i>Blood</i> , 2008, 112, 1786-1786.	0.6	0
512	Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2008, 112, 475-475.	0.6	1
513	Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma.. <i>Blood</i> , 2008, 112, 2049-2049.	0.6	0
514	Genetic Alterations Detected by High-Resolution Array Comparative Genomic Hybridization in Microdissected HRS Cells Correlate with Treatment Outcome in Classical Hodgkin Lymphoma. <i>Blood</i> , 2008, 112, 522-522.	0.6	1
515	Combined FOXP3+ and PD1+ T Cell Density and Architectural Patterns Predict Overall Survival and Risk of Transformation in Uniformly Treated Patients with Follicular Lymphoma. <i>Blood</i> , 2008, 112, 2815-2815.	0.6	2
516	Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma. <i>Blood</i> , 2008, 112, 520-520.	0.6	0
517	High Prevalence of TERT Mutations in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2008, 112, 3126-3126.	0.6	1
518	Prognostic Significance of BCL6 Translocation in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. <i>Blood</i> , 2008, 112, 3782-3782.	0.6	0
519	Lymphomas with Concurrent T(14;18) and 8q24 Translocations Are Under- Reported and Clinical Outcome Depends on the MYC Partner. <i>Blood</i> , 2008, 112, 804-804.	0.6	0
520	Genetic Variation in H2AFX Contributes to Risk of Non-Hodgkin Lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1098-1106.	1.1	37
521	Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression-Based Proliferation Signature. <i>Journal of Clinical Oncology</i> , 2007, 25, 1216-1222.	0.8	166
522	Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. <i>Annals of Oncology</i> , 2007, 18, 535-540.	0.6	66

#	ARTICLE	IF	CITATIONS
523	Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497. <i>Leukemia and Lymphoma</i> , 2007, 48, 2397-2402.	0.6	23
524	CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1102-1109.	0.6	63
525	HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. <i>Leukemia and Lymphoma</i> , 2007, 48, 542-546.	0.6	43
526	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. <i>Journal of Experimental Medicine</i> , 2007, 204, 633-643.	4.2	176
527	A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. <i>Annals of Oncology</i> , 2007, 18, 116-121.	0.6	151
528	Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applicationsâ€”A Study From the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2007, 25, 805-812.	0.8	271
529	The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Blood</i> , 2007, 109, 1857-1861.	0.6	1,193
530	Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. <i>Blood</i> , 2007, 109, 4599-4606.	0.6	226
531	Response: Outcomes with R-CHOP in DLBCL leave ample room for improvement. <i>Blood</i> , 2007, 109, 844-844.	0.6	1
532	Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2007, 110, 4396-4405.	0.6	103
533	Expression of TRAF1 and Nuclear c-Rel Distinguishes Primary Mediastinal Large Cell Lymphoma From Other Types of Diffuse Large B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2007, 31, 106-112.	2.1	77
534	Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. <i>Leukemia</i> , 2007, 21, 2332-2343.	3.3	198
535	A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. <i>Annals of Oncology</i> , 2007, 18, 129-135.	0.6	190
536	Revised Response Criteria for Malignant Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 579-586.	0.8	4,061
537	Whole-Genome Analysis and HLA Genotyping of Enteropathy-Type T-Cell Lymphoma Reveals 2 Distinct Lymphoma Subtypes. <i>Gastroenterology</i> , 2007, 132, 1902-1911.	0.6	240
538	A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2007, 121, 1967-1975.	2.3	8
539	Organochlorines and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2007, 121, 2767-2775.	2.3	121
540	Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 1090-1097.	1.5	36

#	ARTICLE	IF	CITATIONS
541	A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation. <i>Leukemia</i> , 2007, 21, 1532-1544.	3.3	85
542	Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. <i>British Journal of Haematology</i> , 2007, 136, 286-293.	1.2	142
543	Allogeneic Stem Cell Transplantation as Treatment for Relapsed and High-Risk Peripheral T-Cell Lymphoma.. <i>Blood</i> , 2007, 110, 3040-3040.	0.6	2
544	Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: Rituximab Extended Schedule or Re-Treatment Trial (RESORT).. <i>Blood</i> , 2007, 110, 3420-3420.	0.6	14
545	Gene Expression Signatures Predict Overall Survival in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.. <i>Blood</i> , 2007, 110, 348-348.	0.6	11
546	The Architectural Pattern of FOXP3+ T Cells Predicts Risk of Transformation in Patients with Follicular Lymphoma (FL).. <i>Blood</i> , 2007, 110, 358-358.	0.6	3
547	Phase II Study of R-CHOP Followed by 90Y-Ibritumomab Tiuxetan in Untreated Mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499.. <i>Blood</i> , 2007, 110, 389-389.	0.6	35
548	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras.. <i>Blood</i> , 2007, 110, 52-52.	0.6	2
549	CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2007, 110, 692-692.	0.6	2
550	Addition of Rituximab to CHOP Chemotherapy Significantly Improves Survival of Patients with Transformed Lymphoma.. <i>Blood</i> , 2007, 110, 790-790.	0.6	14
551	Both Discordant and Concordant Bone Marrow (BM) Involvement Predict for a Poorer Outcome Independent of the IPI in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP.. <i>Blood</i> , 2007, 110, 1559-1559.	0.6	1
552	High Frequency of 1p36.32 Deletion or Loss of Heterozygosity in Follicular Lymphoma (FL).. <i>Blood</i> , 2007, 110, 183-183.	0.6	1
553	Prognostic Utility of Extranodal Disease Involvement in Diffuse Large B-Cell Lymphoma in Patients Treated with R-CHOP.. <i>Blood</i> , 2007, 110, 1563-1563.	0.6	0
554	CD20 Mutations at the Rituximab Binding Site Are Rare and Are Not a Significant Cause of R-CHOP Resistance in Patients with De Novo Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2007, 110, 686-686.	0.6	2
555	Distinct Genetic Aberrations in Molecular Subtypes of Diffuse Large B Cell Lymphoma Detected by Array CGH.. <i>Blood</i> , 2007, 110, 2631-2631.	0.6	2
556	Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations.. <i>Blood</i> , 2007, 110, 360-360.	0.6	7
557	Gene Expression Model of Survival and Transformation in Follicular Lymphoma (FL): A Study by the LLMP.. <i>Blood</i> , 2007, 110, 2606-2606.	0.6	0
558	Major Histocompatibility Class II (MHCII) and Germinal Center Associated Gene Expression Correlate with Overall Survival in Rituximab and CHOP-Like Treated Diffuse Large B Cell Lymphoma (DLBCL) Patients Using Formalin Fixed Paraffin Embedded (FFPE) Tissues.. <i>Blood</i> , 2007, 110, 50-50.	0.6	1

#	ARTICLE	IF	CITATIONS
559	Vascularization Predicts Overall Survival (OS) & Risk of Transformation (RT) in Uniformly Treated Patients with Follicular Lymphoma (FL).. Blood, 2007, 110, 184-184.	0.6	0
560	The Role of Hepatitis C Virus Infection and Non-Hodgkin Lymphoma in Canada. American Journal of Epidemiology, 2006, 163, S89-S89.	1.6	0
561	Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood, 2006, 107, 4207-4213.	0.6	248
562	Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood, 2006, 108, 311-318.	0.6	113
563	Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood, 2006, 108, 3295-3301.	0.6	559
564	Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma*. British Journal of Haematology, 2006, 133, 634-637.	1.2	27
565	Four human t(11;14)(q13;q32)-containing cell lines having classic and variant features of Mantle Cell Lymphoma. Leukemia Research, 2006, 30, 449-457.	0.4	29
566	Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 3121-3127.	0.8	1,203
567	BCL2 Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 961-968.	0.8	277
568	Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Annals of Oncology, 2006, 17, 123-130.	0.6	212
569	Molecular Diagnosis of Burkitt's Lymphoma. New England Journal of Medicine, 2006, 354, 2431-2442.	13.9	824
570	Mutation and genomic deletion status of ataxia telangiectasia mutated(ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2352-2357.	3.3	138
571	Clinicopathologic Subtypes of Mantle Cell Lymphoma (MCL) Show Distinct Patterns of Genetic Copy Number Alteration.. Blood, 2006, 108, 2049-2049.	0.6	1
572	The Tumor Microenvironment Measured by Flow Cytometry Predicts Overall Survival (OS) and Transformation Risk (TR) in Follicular Lymphoma.. Blood, 2006, 108, 2406-2406.	0.6	5
573	Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 356-356.	0.6	2
574	Gene Expression Differences between Low and High Stage Diffuse Large B Cell Lymphoma (DLBCL).. Blood, 2006, 108, 809-809.	0.6	13
575	Strong p53 Expression Is an Independent Predictor of Outcome in De Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Either CHOP or CHOP-R.. Blood, 2006, 108, 812-812.	0.6	15
576	Addition of Rituximab (R) to CHOP Improves Survival in the Non-GCB Subtype of Diffuse Large B Cell Lymphoma (DLBCL).. Blood, 2006, 108, 816-816.	0.6	6

#	ARTICLE	IF	CITATIONS
577	Long Term Results of Myeloablative Allogeneic Stem Cell Transplantation Using Related and Unrelated Donors in Patients with Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.. Blood, 2006, 108, 3139-3139.	0.6	0
578	Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.. Blood, 2006, 108, 2739-2739.	0.6	0
579	Bone Marrow (BM) Involvement in Diffuse Large B Cell Lymphoma (DLBCL): Clinical Impact of Discordant Disease.. Blood, 2006, 108, 2031-2031.	0.6	0
580	Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.. Blood, 2006, 108, 3039-3039.	0.6	0
581	Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.. Blood, 2006, 108, 3662-3662.	0.6	7
582	Structural Profiles of p53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-Cell Lymphoma: An International Collaborative Study.. Blood, 2006, 108, 811-811.	0.6	0
583	Correlation of DNA Copy Number, Gene Expression, Protein Expression and Clinical Outcome in a Group of Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with CHOP Plus Rituximab (CHOP-R).. Blood, 2006, 108, 2027-2027.	0.6	0
584	High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood, 2005, 106, 1473-1478.	0.6	112
585	Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood, 2005, 107, 1101-1107.	0.6	68
586	Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood, 2005, 106, 2169-2174.	0.6	427
587	Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood, 2005, 106, 4315-4321.	0.6	330
588	Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Columbia. British Journal of Haematology, 2005, 128, 792-796.	1.2	37
589	Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma*. British Journal of Haematology, 2005, 131, 223-230.	1.2	78
590	Expression pattern of intracellular leukocyte-associated proteins in primary mediastinal B cell lymphoma. Leukemia, 2005, 19, 856-861.	3.3	23
591	ALK-positive diffuse large B-cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomas. Leukemia, 2005, 19, 1839-1840.	3.3	41
592	Amplification ofIGH/MYC fusion in clinically aggressiveIGH/BCL2-positive germinal center B-cell lymphomas. Genes Chromosomes and Cancer, 2005, 43, 414-423.	1.5	37
593	The treatment of primary central nervous system lymphoma in 122 immunocompetent patients. Cancer, 2005, 103, 1008-1017.	2.0	48
594	Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia. Journal of Clinical Oncology, 2005, 23, 5027-5033.	0.8	874

#	ARTICLE	IF	CITATIONS
595	Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2005, 46, 693-701.	0.6	51
596	Molecular Pathogenesis of Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 6370-6378.	0.8	172
597	Hematopathology Approaches to Diagnosis and Prognosis of Indolent B-Cell Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 299-306.	0.9	6
598	High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2005, 23, 7994-8002.	0.8	62
599	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , 2005, 106, 3183-3190.	0.6	348
600	Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. <i>Leukemia and Lymphoma</i> , 2005, 46, 1721-1727.	0.6	55
601	Mantle cell lymphoma in the ocular adnexal region. <i>Ophthalmology</i> , 2005, 112, 114-119.	2.5	89
602	<i>Helicobacter pylori</i> and MALT Lymphoma. <i>Gastroenterology</i> , 2005, 128, 1579-1605.	0.6	184
603	Revised Response Criteria for Malignant Lymphomas From the Members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma, Represented by... <i>Blood</i> , 2005, 106, 18-18.	0.6	12
604	Survival of Limited Stage Peripheral T-Cell Lymphoma Is Similar To Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2005, 106, 2817-2817.	0.6	1
605	Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B.. <i>Blood</i> , 2005, 106, 349-349.	0.6	77
606	Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).. <i>Blood</i> , 2005, 106, 492-492.	0.6	7
607	Insights into Disease Evolution of Transformed Follicular Lymphoma Derived from Cytogenetics.. <i>Blood</i> , 2005, 106, 604-604.	0.6	1
608	Towards the Human Cancer Genome Project: A Sequence-Ready Physical Map of a Follicular Lymphoma Genome.. <i>Blood</i> , 2005, 106, 605-605.	0.6	0
609	CD56+ Monomorphic Enteropathy-Type T-Cell Lymphoma Is a Genetically Distinct Entity Characterized by 8q Gains and Lack of 1q and 5q Gains.. <i>Blood</i> , 2005, 106, 2840-2840.	0.6	0
610	BCL11AXL Protein: Its Distribution in Normal and Malignant Tissues and Use as a Marker for Plasmacytoid Dendritic Cells.. <i>Blood</i> , 2005, 106, 4392-4392.	0.6	0
611	Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. <i>Clinical Cancer Research</i> , 2005, 11, 1065-72.	3.2	130
612	Low-Grade Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2004, 2004, 203-220.	0.9	47

#	ARTICLE	IF	CITATIONS
613	Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 2004, 127, 311-321.	1.2	46
614	Molecular Signatures of Lymphoma. <i>International Journal of Hematology</i> , 2004, 80, 401-409.	0.7	13
615	Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. <i>Genes Chromosomes and Cancer</i> , 2004, 39, 195-204.	1.5	114
616	Delineation of a minimal region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial chromosome contig spanning a 6-megabase region of 6q16-q21. <i>Genes Chromosomes and Cancer</i> , 2004, 40, 60-65.	1.5	26
617	Immunohistochemical investigation of SV40 large T antigen in Hodgkin and non-Hodgkin's lymphoma. <i>International Journal of Cancer</i> , 2004, 112, 533-535.	2.3	25
618	Improved Outcome of Human Immunodeficiency Virus-Associated Plasmablastic Lymphoma of the Oral Cavity in the Era of Highly Active Antiretroviral Therapy: A Report of Two Cases. <i>Leukemia and Lymphoma</i> , 2004, 45, 1881-1885.	0.6	56
619	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , 2004, 103, 275-282.	0.6	3,574
620	The Spectrum of Lymphoma with 8q24 Aberrations: A Clinical, Pathological and Cytogenetic Study of 87 Consecutive Cases. <i>Leukemia and Lymphoma</i> , 2004, 45, 519-528.	0.6	65
621	Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. <i>Human Molecular Genetics</i> , 2004, 13, 1827-1837.	1.4	115
622	Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. <i>New England Journal of Medicine</i> , 2004, 351, 2159-2169.	13.9	1,293
623	BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2004, 165, 159-166.	1.9	262
624	Emerging prognostic factors in diffuse large B cell lymphoma. <i>Current Opinion in Oncology</i> , 2004, 16, 436-441.	1.1	40
625	Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. <i>Blood</i> , 2004, 103, 4251-4258.	0.6	296
626	Mechanisms of Bcl-2 Protein Expression in Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2004, 104, 26-26.	0.6	9
627	Transformed Lymphoma: Incidence and Long-Term Outcome.. <i>Blood</i> , 2004, 104, 3253-3253.	0.6	3
628	Lymphoma-Associated Macrophage (LAM) Content Is an Independent Predictor of Survival in Patients with Follicular Lymphoma (FL).. <i>Blood</i> , 2004, 104, 3259-3259.	0.6	1
629	Phase II Trial of Bortezomib in Mantle Cell Lymphoma.. <i>Blood</i> , 2004, 104, 608-608.	0.6	25
630	Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphoblastic Lymphoma (T-LBL) : An Intention to Treat Analysis.. <i>Blood</i> , 2004, 104, 900-900.	0.6	2

#	ARTICLE	IF	CITATIONS
631	HLA-DR Protein Status Predicts Survival in Patients with Diffuse Large B Cell Lymphoma (DLBCL) Treated with the MACOP-B Chemotherapy Regimen.. Blood, 2004, 104, 3273-3273.	0.6	0
632	Acceptable Outcomes for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) for Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).. Blood, 2004, 104, 3325-3325.	0.6	0
633	Gene Expression Profiling, Frozen and Paraffin Section Immunohistochemistry, and In Situ Hybridization for Determination of Monoclonality in Diffuse Large B-Cell Lymphoma.. Blood, 2004, 104, 4553-4553.	0.6	0
634	High Cyclin D1 Expression Is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and Is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA.. Blood, 2004, 104, 697-697.	0.6	0
635	Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).. Blood, 2004, 104, 415-415.	0.6	1
636	Long-Term Results of Allogeneic Hematopoietic Stem Cell Transplantation Using Unrelated or HLA Mismatched Family Donors for Acute and Chronic Lymphoid Malignancy.. Blood, 2004, 104, 2764-2764.	0.6	0
637	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 2003, 3, 185-197.	7.7	848
638	Characterization of the recurrent translocation t(1;1)(p36.3;q21.1-2) in non-Hodgkin lymphoma by multicolor banding and fluorescence in situ hybridization analysis. Genes Chromosomes and Cancer, 2003, 36, 375-381.	1.5	30
639	Non-muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes and Cancer, 2003, 37, 427-432.	1.5	131
640	Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. British Journal of Haematology, 2003, 120, 424-433.	1.2	118
641	Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. British Journal of Haematology, 2003, 122, 745-759.	1.2	39
642	Multicolor Karyotyping and Clinicopathological Analysis of Three Intravascular Lymphoma Cases. Modern Pathology, 2003, 16, 716-724.	2.9	46
643	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. Journal of Experimental Medicine, 2003, 198, 851-862.	4.2	1,002
644	Prominent intrasinusoidal infiltration of the bone marrow by mantle cell lymphoma. Human Pathology, 2003, 34, 789-791.	1.1	15
645	MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. Blood, 2003, 101, 4539-4546.	0.6	188
646	Molecular Pathogenesis of Mucosal-Associated Lymphoid Tissue (MALT) Lymphoma. Leukemia and Lymphoma, 2003, 44, S13-S20.	0.6	15
647	Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 2003, 21, 1740-1745.	0.8	261
648	ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood, 2003, 102, 2568-2573.	0.6	281

#	ARTICLE	IF	CITATIONS
649	Distinguishing between immunophenotype and genotype in non-Hodgkin's lymphomas. <i>Psychophysiology</i> , 2003, 2, 443-4.	1.1	0
650	Aberrant expression of T-plastin in Sezary cells. <i>Cancer Research</i> , 2003, 63, 7122-7.	0.4	60
651	Treatment of Elderly Hodgkin's Lymphoma Patients with a Novel 5-drug Regimen (ODBEP): A Phase II Study. <i>Leukemia and Lymphoma</i> , 2002, 43, 1395-1402.	0.6	36
652	Primary Cutaneous Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2002, 117, 574-580.	0.4	44
653	Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1. <i>Leukemia</i> , 2002, 16, 276-283.	3.3	10
654	Cytogenetic Analysis in Mantle Cell Lymphoma: A Review of 214 Cases. <i>Leukemia and Lymphoma</i> , 2002, 43, 783-791.	0.6	54
655	Evidence for Early Infection of Nonneoplastic Natural Killer Cells by Epstein-Barr Virus. <i>Journal of Virology</i> , 2002, 76, 11139-11142.	1.5	35
656	Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. <i>Blood</i> , 2002, 99, 618-626.	0.6	257
657	The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 1937-1947.	13.9	3,474
658	Brief Chemotherapy and Involved-Region Irradiation for Limited-Stage Diffuse Large-Cell Lymphoma: An 18-Year Experience From the British Columbia Cancer Agency. <i>Journal of Clinical Oncology</i> , 2002, 20, 197-204.	0.8	99
659	Cytogenetic findings in reactive lymphoid hyperplasia: Significance of non-clonal t(3;14) and t(3;22). <i>American Journal of Hematology</i> , 2002, 70, 133-138.	2.0	11
660	Uncovering novel inter- and intrachromosomal chromosome 1 aberrations in follicular lymphomas by using an innovative multicolor banding technique. <i>Genes Chromosomes and Cancer</i> , 2002, 34, 201-210.	1.5	21
661	Heavy multinodular cutaneous lymphoid infiltrates: clinicopathologic features and B-cell clonality. <i>Journal of Cutaneous Pathology</i> , 2002, 29, 159-167.	0.7	28
662	CD5-positive diffuse large B-cell lymphoma: a distinct entity?. <i>Advances in Anatomic Pathology</i> , 2002, 9, 269-270.	2.4	0
663	Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma. <i>Cancer Research</i> , 2002, 62, 4089-94.	0.4	46
664	MALT Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2001, 2001, 241-258.	0.9	130
665	MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. <i>Blood</i> , 2001, 97, 3902-3909.	0.6	166
666	Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. <i>Blood</i> , 2001, 98, 2837-2844.	0.6	125

#	ARTICLE	IF	CITATIONS
667	Leukaemic infiltration of an adenocarcinoma effusion. <i>British Journal of Haematology</i> , 2001, 112, 257-257.	1.2	0
668	Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). <i>Genes Chromosomes and Cancer</i> , 2001, 30, 375-382.	1.5	142
669	Systemic anaplastic large-cell lymphoma: Results from the non-Hodgkin's lymphoma classification project. <i>American Journal of Hematology</i> , 2001, 67, 172-178.	2.0	47
670	Involvement of the X chromosome in non-Hodgkin lymphoma. <i>Genes Chromosomes and Cancer</i> , 2000, 28, 246-257.	1.5	40
671	Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2000, 25, 605-612.	1.3	66
672	TNFR-Associated Factor Family Protein Expression in Normal Tissues and Lymphoid Malignancies. <i>Journal of Immunology</i> , 2000, 165, 5084-5096.	0.4	135
673	Clinical Significance of the t(14;18) AndBCL2Overexpression in Follicular Large Cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2000, 36, 513-523.	0.6	23
674	Lymphoma With Follicular and Monocytoid B-Cell Components. <i>American Journal of Clinical Pathology</i> , 2000, 114, 516-522.	0.4	20
675	Blastic Mantle Cell Leukemia: An Unusual Presentation of Blastic Mantle Cell Lymphoma. <i>Modern Pathology</i> , 2000, 13, 825-833.	2.9	57
676	Involvement of the X chromosome in non-Hodgkin lymphoma. , 2000, 28, 246.		1
677	Small Noncleaved, Non-Burkitt's (Burkitt-Like) Lymphoma: Cytogenetics Predict Outcome and Reflect Clinical Presentation. <i>Journal of Clinical Oncology</i> , 1999, 17, 1558-1558.	0.8	169
678	Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma. <i>Blood</i> , 1999, 93, 3913-3921.	0.6	464
679	Concurrent chromosomal alterations at 3q27, 8q24 and 18q21 in B-cell lymphomas. <i>British Journal of Haematology</i> , 1999, 105, 437-440.	1.2	33
680	Anaplastic large cell lymphoma: a clinicopathologic analysis. , 1999, 17, 137-148.		37
681	Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. <i>Lancet, The</i> , 1999, 354, 1698-1699.	6.3	111
682	Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: Correlation with 3q27 and 18q21 chromosomal abnormalities. <i>Human Pathology</i> , 1999, 30, 803-808.	1.1	125
683	Anaplastic large cell lymphoma: a clinicopathologic analysis. <i>Hematological Oncology</i> , 1999, 17, 137-148.	0.8	2
684	Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. <i>Bone Marrow Transplantation</i> , 1998, 22, 981-987.	1.3	101

#	ARTICLE	IF	CITATIONS
685	Clinicopathological Analysis of Follicular Lymphoma with a Polyploid Karyotype. <i>Leukemia and Lymphoma</i> , 1998, 28, 383-389.	0.6	5
686	Molecular Methods for Detecting t(11;14) Translocations in Mantle-Cell Lymphomas. <i>Diagnostic Molecular Pathology</i> , 1998, 7, 209-214.	2.1	25
687	Immunohistochemical Analysis of bcl-2, bax, mcl-1, and bcl-X Expression in Ovarian Surface Epithelial Tumors. <i>International Journal of Gynecological Pathology</i> , 1998, 17, 255-260.	0.9	24
688	Homozygous Deletions at Chromosome 9p21 Involving p16 and p15 Are Associated With Histologic Progression in Follicle Center Lymphoma. <i>Blood</i> , 1998, 91, 4677-4685.	0.6	158
689	t(2;5) Positive Lymphoma with Peripheral Blood Involvement. <i>Leukemia and Lymphoma</i> , 1998, 28, 415-422.	0.6	24
690	Histologic Features and Differential Diagnosis of Nodular Lymphocyte Predominance Hodgkin's Lymphoma (NLPHL). <i>American Journal of Surgical Pathology</i> , 1998, 22, 131-133.	2.1	0
691	Origin of the Hodgkin/Reed-Sternberg Cells in Chronic Lymphocytic Leukemia With "Hodgkin's Transformation". <i>Blood</i> , 1998, 91, 1757-1761.	0.6	1
692	Homozygous Deletions at Chromosome 9p21 Involving p16 and p15 Are Associated With Histologic Progression in Follicle Center Lymphoma. <i>Blood</i> , 1998, 91, 4677-4685.	0.6	97
693	Clinical Utility of Heteroduplex Analysis of TCR Gamma Gene Rearrangements in the Diagnosis of T-Cell Lymphoproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 1997, 108, 295-301.	0.4	51
694	Bone Marrow Involvement in T-Cell "Rich B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 1997, 108, 570-578.	0.4	50
695	PATHOLOGIC PROGNOSTIC FACTORS IN DIFFUSE AGGRESSIVE NON-HODGKIN'S LYMPHOMA. <i>Hematology/Oncology Clinics of North America</i> , 1997, 11, 847-862.	0.9	23
696	Mantle Cell Lymphoma: A Clinicopathologic Study of 80 Cases. <i>Blood</i> , 1997, 89, 2067-2078.	0.6	448
697	Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma. <i>Blood</i> , 1997, 90, 244-251.	0.6	451
698	Bcl-6 and Lymphoproliferative Disorders. <i>Leukemia and Lymphoma</i> , 1997, 26, 515-525.	0.6	7
699	U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data analysis and interpretation. , 1997, 30, 236-244.		116
700	Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma. <i>Blood</i> , 1997, 90, 244-251.	0.6	9
701	Spontaneous regression of chemotherapy-refractory non-hodgkin's lymphoma preceding the development of secondary leukaemia. <i>Leukemia and Lymphoma</i> , 1996, 20, 351-353.	0.6	0
702	A Single-institution Perspective. <i>American Journal of Surgical Pathology</i> , 1996, 20, 373-375.	2.1	0

#	ARTICLE	IF	CITATIONS
703	Comparison of Cytogenetic Analysis, Southern Analysis, and Polymerase Chain Reaction for the Detection of t(14; 18) in Follicular Lymphoma. American Journal of Clinical Pathology, 1995, 103, 472-478.	0.4	207
704	Frequent association of t(3;14) or variant with other lymphoma-specific translocations. British Journal of Haematology, 1995, 89, 569-575.	1.2	31
705	Simultaneous Development of Diffuse Immunoblastic Lymphoma in Recipients of Renal Transplants From a Single Cadaver Donor: Transmission of Epstein-Barr Virus and Triggering by OKT3. American Journal of Kidney Diseases, 1994, 23, 130-134.	2.1	18
706	Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3. British Journal of Haematology, 1993, 83, 158-165.	1.2	74
707	T-cell receptor variable region gene expression in cutaneous T-cell lymphomas. Journal of Cutaneous Pathology, 1992, 19, 21-26.	0.7	19
708	Histopathologic, immunophenotypic and genotypic analyses in ocular adnexal lymphoproliferative disorders. Australian and New Zealand Journal of Ophthalmology, 1992, 20, 247-251.	0.4	7
709	t(11;18)(q21;q21.1): A recurring translocation in lymphomas of mucosa-associated lymphoid tissue (malt)? Genes Chromosomes and Cancer, 1992, 4, 183-187.	1.5	98
710	Translocation t(3;3)(q21;q26) and thrombocytosis. Cancer Genetics and Cytogenetics, 1986, 22, 365.	1.0	9
711	Molecular pathology of lymphoma. , 0, , 257-276.		0